Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07446439 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Name: A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use — clinical trial record (NCT07446439)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorVanda Pharmaceuticals

Started2026-03-27

View on ClinicalTrials.gov ↗

Amendment history

2026-04-14

Study Identification, Study Status, Contacts/Locations v1

Recruitment opened

Trial sites expanded: 2 → 10 locations

Start dateestimated 2026-02-25→confirmed 2026-03-27

2026-02-25

Original filing

Vanda Pharmaceuticals

23 trials monitored

See 3 trials at risk

Obesity

3,523 trials monitored

See 133 trials at risk

The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

Trial Details

NCT Number	NCT07446439
Lead Sponsor	Vanda Pharmaceuticals
Conditions	Nausea and Vomiting, Obesity
Enrollment	280 participants
Start Date	2026-03-27
Primary Completion	2026-12-01 (estimated)
Study Completion	2026-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-20